Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591085 | 0.92 | SIGMAR1 (0.30) | SIGMAR1HTR2A | |
| SCHEMBL3713177 | 0.79 | SIGMAR1 (0.30) | SIGMAR1HTR2A | |
| SCHEMBL21591186 | 0.78 | — | — | |
| SCHEMBL16035833 | 0.78 | — | — | |
| SCHEMBL15775921 | 0.78 | — | — | |
| SCHEMBL3962371 | 0.74 | — | — | |
| SCHEMBL19358647 | 0.72 | — | — | |
| SCHEMBL14373183 | 0.70 | — | — | |
| SCHEMBL15958465 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL31704772 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3594202-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-11 | — | — | EP | claimed |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-15 | — | — | US | claimed |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-17 | — | — | US | claimed |
| EP-3594202-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-11 | — | — | EP | disclosed |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-15 | — | — | US | disclosed |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-17 | — | — | US | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | SIGMAR1 4278/4885HTR2A 2205/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | SIGMAR1 4136/4885HTR2A 2377/4885 |
| US-11034700-B2 | Substituted pyrrolidine compound and use thereof | HCRTR2, HCRTR1, CRHR2 | SIGMAR1 252/4885HTR2A 96/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | SIGMAR1 4136/4885HTR2A 2377/4885 |
| US-20200392149-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CRHR2 | SIGMAR1 252/4885HTR2A 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.